News
01-08-2010, 04:21 AM
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.
More... (http://www.news-medical.net/news/20100108/Novelos-Therapeutics-to-conclude-pivotal-Phase-3-trial-in-advanced-non-small-cell-lung-cancer.aspx)
More... (http://www.news-medical.net/news/20100108/Novelos-Therapeutics-to-conclude-pivotal-Phase-3-trial-in-advanced-non-small-cell-lung-cancer.aspx)